Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.Megan McNamara, Stephen J. Freedland, Krishnan Ramaswamy et al.|Journal of Clinical Oncology|2019Cited by 36